Yifeng Pharmary(SH:603939) Shang Hai Zheng Quan Bao·2025-11-24 18:41Group 1 - The company announced the repurchase and cancellation of 25,516 restricted stocks from five incentive targets due to their departure, demotion, or failure to meet performance standards as per the 2022 Restricted Stock Incentive Plan [1][3][4] - The decision for the stock repurchase was approved during the board meeting on September 30, 2025, and legal opinions were provided by Hunan Qiyuan Law Firm [2][6] - The repurchase will be executed at the grant price plus bank interest, and the company has applied for the necessary procedures with the China Securities Depository and Clearing Corporation [4][6] Group 2 - The company confirmed that all procedures and disclosures related to the stock repurchase comply with relevant laws and regulations, ensuring no harm to the rights of the incentive targets or creditors [5][6] - The repurchase and cancellation of the restricted stocks will be completed by November 27, 2025, and the company will handle the necessary business registration changes thereafter [4][6] - The company will hold a third-quarter performance briefing on December 2, 2025, to discuss its operational results and financial status with investors [9][10]